Arcturus Therapeutics
ARCT
111 hedge funds and large institutions have $379M invested in Arcturus Therapeutics in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 20 closing their positions.
123% more call options, than puts
Call options by funds: $6.67M | Put options by funds: $2.99M
15% more capital invested
Capital invested by funds: $328M → $379M (+$50.7M)
3% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 36
0.92% more ownership
Funds ownership: 83.4% → 84.32% (+0.92%)
4% less funds holding
Funds holding: 116 → 111 (-5)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.7M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$11.6M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$10.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.98M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.64M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.24M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.95M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.18M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$1.93M |
ARCT Hedge Fund Activity: Q4 2022 in Review
111 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2022, worth a combined $379M — up 15% from $328M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ARCT and 18 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 37 added.
The largest buyer was Federated Hermes, adding an estimated $11.7M. The largest seller was Point72 Asset Management, cutting an estimated $9.64M.
- 111 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2022, down from 116 in Q3 2022.
- Funds reported $379M of Arcturus Therapeutics stock for Q4 2022, up 15% quarter-over-quarter.
- 18 funds opened new Arcturus Therapeutics positions in Q4 2022 and 20 closed out, a net change of -2 holders.
- The largest Arcturus Therapeutics buyer in Q4 2022 was Federated Hermes, an estimated $11.7M added.
- The largest Arcturus Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $9.64M sold.
Based on aggregated 13F filings for Q4 2022.